Lantern Pharma Reports LP-300 Shows 8.3-Month Progression-Free Survival in EGFR L858R Lung Cancer After Targeted Therapy Failure
Lantern Pharma announced emerging clinical data showing its investigational drug LP-300 achieved an 8.3-month median progression-free survival (PFS) in patients with EGFR L858R-mutant non-small cell lung cancer after failure of prior targeted therapies. The results come from the ongoing Phase 2 HARMONIC trial and suggest improved outcomes in a high-risk patient subgroup, particularly those who completed more treatment cycles. Importantly, LP-300 demonstrated no new safety signals when combined with standard chemotherapy, supporting its potential as a tolerable option for this hard-to-treat population. 
Lantern Pharma Reports LP-300 Shows 8.3-Month Progression-Free Survival in EGFR L858R Lung Cancer After Targeted Therapy Failure